[The labyrinth of residual risk: reduction of the remaining lipid and inflammation risk in the prevention of atherosclerosis].

[The labyrinth of residual risk: reduction of the remaining lipid and inflammation risk in the prevention of atherosclerosis]. Orv Hetil. 2018 Jan;159(4):124-130 Authors: Márk L, Harangi M, Paragh G Abstract Since cardiovascular diseases are the main cause of mortality worldwide, the reduction of their risk is a crucial point of present-day medicine. It has been proven unequivocally that the administration of various treatments has a favorable effect on the frequency of cardiovascular events and on the atherosclerosis leading to them. Although systematic and guideline-driven administration of these drugs has led to a decrease in the incidence and mortality of vascular events, the leading position of this group of diseases in mortality and morbidity has not changed. That is why medicine, besides keeping up actual guidelines optimally, is always searching for new modalities to further decrease residual risk. This residual risk can be diverse. The present paper summarizes the possibilities of reducing residual lipid and residual inflammatory risk after treatment according to the guidelines. It has been proven that lowering LDL-cholesterol below 1.8 mmol/l has a further advantage on the occurrence of vascular events. Treating the elevated lipoprotein(a), triglyceride and low HDL-cholesterol levels should decrease the residual lipid risk. Statins and statin-ezetimibe combination, besides lipid modulation, have an anti-inflammatory effect...
Source: Orvosi Hetilap - Category: General Medicine Authors: Tags: Orv Hetil Source Type: research